Family fights for funding to treat daughter’s rare condition

August 5, 2013 by 

A St. Albert couple is waging a fight with the Alberta government for their daughter’s life.

Laura and Dane Sadownyk live in Erin Ridge with their three-year-old daughter Aleena who, earlier this year, was diagnosed with an extremely rare condition called MPS VI, or Maroteaux-Lamy Syndrome. Treatment is available, but could cost anywhere from $300,000 to $1 million a year, and the family is working with a foundation out of Ontario to get the province to fund treatment through its Short-term Exceptional Drug Therapy Program.

St. Albert

The parents of three-year-old Aleena Sadownyk are fighting to have treatment for their daughter’s rare medical condition funded by the Alberta government. (Photo supplied)

“It’s devastating to hear your child has any kind of condition that not only is rare, but takes time to find,” Dane said. “We’ve been through a wide range of emotions, for sure, as parents. You’re trying to absorb it all; it’s surreal at times.”

Currently, there are only nine cases of MPS VI in Canada and 1,100 worldwide. Sufferers lack an enzyme in their blood that breaks down cellular waste called glycosaminoglycan (GAG). This waste then builds up in bones, tissues, organs and muscles, causing heart and lung disease, stiffened joints, shortened stature and premature death.

Aleena was diagnosed with MPS VI in April, and since then, Dane said that she has dealt with it pretty well.

“She does have a very keen sense of what’s going on around her,” he said. “When your daughter starts asking questions like, ‘Are we going to the doctor today?’ and things of that nature, you know they’re sensing there’s something going on.”

There is no cure for MPS VI, but it can be managed through an enzyme replacement therapy called Naglazyme, which infuses small doses of a synthetic version of the enzyme Aleena is lacking on a weekly basis.

However, given how expensive treatment is, the Sadownyks need help from the provincial government. They have already applied to the Alberta Rare Disease Funding Program, but were told that was not the right program because Naglazyme had not been given general market approval through Health Canada.

“My heart goes out to the Sadownyk family. I know they want to do everything they can to help their daughter,” Alberta Health Minister Fred Horne said in a statement emailed to the Leader.

Health Minister Fred Horne. (IAN KUCERAK, Sun Media News Services)

Health Minister Fred Horne. (Sun Media News Services)

“Because [Naglazyme] doesn’t have federal approval, the options for funding this drug are different than for some other drugs. … [The Short-term Exceptional Drug Therapy Program] relies on medical experts to assess whether a specific drug will be safe and effective for a specific patient. It’s done on a case-by-case basis, so it can take a patient’s needs and particular health condition into account.”

Helping the Sadownyks fight their battle is the Isaac Foundation out of Ontario, headed up by Andrew McFadyen, whose son Isaac was also diagnosed with MPS VI in 2006 when he was 18 months old. He has been receiving Naglazyme treatment for about seven years and is doing “extremely well,” his dad said, and that has inspired him to help other families get the treatment they need.

“When Isaac was diagnosed, we were told there was a treatment available, but we were told by our physician, ‘Don’t even think about it because you’ll never get it here in Canada,’” McFadyen said. “For us, the only thing we could do is fight for our child, so that’s what we did. We made sure we could bring it to Canada, then we made sure we could deal with the bureaucrats to get it funded in Canada. From that, there was precedent set.”

McFadyen has helped families fight for Naglazyme funding in British Columbia, Saskatachewan and Quebec. But dealing with the Alberta government has been frustrating.

“It just seems kind of silly that a group of bureaucrats are going to sit down in a room again and review the same data and make a decision on the fate of this little girl based on what they do or do not know about the drug,” he said.

While the Sadownyks would like to get Aleena started on Naglazyme as soon as possible and say it “means the world” to have someone like McFadyen on their side, there is no set timeline for a decision from the provincial government.

“As a politician, I don’t get directly involved in assessing which drugs would be funded through that process — and appropriately leave that assessment to medical experts,” Horne said in his statement. “Department officials will continue to support the application process, a clinical review is underway now and I understand we expect a response soon.”

Meanwhile, Dane is holding out hope that treatment can begin as soon as possible.

“We have more hope now than if we were trying to navigate this on our own,” he said. “Having said that, I’ll never feel completely satisfied as a parent until the day comes and we can take her in for those treatments.”

— GLENN COOK, St. Albert Leader

St Albert toddler has rare disease

Edmonton, AB, Canada / 630 CHED

August 02, 2013 02:51 pm
Some last minute negotiations began Friday between Alberta Health and an organization known as the Isaac Foundation, to get dire help for the family of a St Albert toddler.
Aleena Sadownyk has an extremely rare condition that has left the three year old with an enzyme deficiency, that’s breaking down her little body.

They are seeking treatment with a drug called Naglazyme.

“Alberta Health gave me a call to reiterate the fact that they’re working on this file and to tell us that they’re hopeful to have an expedited review and will render a decision soon,” said Andrew McFayden of the Isaac Foundation who has gone to bat for the family.
The Sadownyk family has been asking about the province’s Short Term Exceptional Drug Therapy program after originally turning them down through the Alberta Rare Diseases Funding Program.

“What that means I don’t know. I asked about timelines and bench marks and that sort of thing so that the family could make sure they were close to hearing the fate of their daughter buy I haven’t been able to get much of an update as far as time line.”
McFayden says the treatment has worked on seven other instances in Canada, including his own son.

Late Friday afternoon, Health Minister Fred Horne’s office issued a statement.
“My heart goes out to the Sadownyk family. I know they want to do everything they can to help their daughter. The family has contacted my office recently and were immediately put in touch with appropriate officials who could assist in supporting the family in making a funding request through appropriate programs.

As things stand, Naglazyme has not yet received general market approval through Health Canada. Because it doesn’t have federal approval, the options for funding this drug are different than for some other drugs. Albertans who need access to high-cost drug therapies not already covered by provincial programs may explore funding options through the Short-term Exceptional Drug Therapy Program. That program relies on medical experts to assess whether a specific drug will be safe and effective for a specific patient. It’s done on a case-by-case basis, so it can take a patient’s needs and particular health condition into account.

“As a politician, I don’t get directly involved in assessing which drugs would be funded through that process — and appropriately leave that assessment to medical experts. Department officials will continue to support the application process, a clinical review is underway now and I understand we expect a response soon.”

McFayden says time is of the essence.

“It’s tough that we’re going into a long weekend and to be honest with you, if I thought we could wait, we would have put this out on Tuesday, but I think the sooner a decision gets rendered the better, because even after a decision is rendered if it is a positive decision, and there’s no guarantee whatsoever the province is even going to say yes, then we’d have to ensure that the hospital staff will be trained.”

Officials from the drug supplier would come in from California to train the staff at the Stollery.

Fund life-saving treatment for St. Albert toddler now: Forsyth

CALGARY, AB (August 2, 2013): The PC government needs to immediately commit to funding a life-saving drug for a three-year-old Alberta girl with an extremely rare, life-threatening disease, Wildrose Health Critic Heather Forsyth said today.

The girl, Aleena Sadownyk of St. Albert, was diagnosed in April with MPS VI, an enzyme deficiency disease that occurs in one out of approximately 250,000 to 600,000 newborn babies. If left untreated, it will cause life-threatening complications including heart problems, breathing difficulties and skeletal deformations.

The treatment, Naglazyme, has proven successful in other patients suffering from MPS VI, including seven other Canadian children who are currently receiving this treatment in neighbouring provinces. It costs approximately $300,000 annually. BC, Saskatchewan, Ontario and Quebec have all agreed to fund Naglazyme for MPS VI patients.

Today, Forsyth sent a letter to Health Minister Fred Horne formally requesting he approve funding for Aleena’s treatment.

“This treatment is Aleena’s only hope,” Forsyth said. “Today, I join with the Sadownyk family in making this simple but critical request of the Alberta government: Please fund this life-saving treatment for Aleena.”

Forsyth said the Sadownyk family has attempted to raise Aleena’s extraordinary case with their local MLA and with Horne but has had little success. The government has already denied the family’s first funding request through the Alberta Rare Diseases Funding Program. A second request through the Short Term Exceptional Drug Therapy Program has received no response.

“This family is desperate to save their daughter’s life,” Forsyth said. “Aleena needs this treatment and she needs it now. Every day that access is delayed, is another day for irreversible complications to take hold. Other provinces have stepped up when their children needed this treatment. It’s time for Alberta to do the same.”

Heather Forsyth
Calgary-Fish Creek
Heather Forsyth was first elected on June 15, 1993 as the MLA for Calgary-Fish Creek, and acts as the Wildrose Health critic.

Source: http://www.wildrose.ca/feature/fund-life-saving-treatment-for-st-albert-toddler-now-forsyth/